Newcastle Disease Virus Hemagglutinin Neuraminidase As a Potential Cancer Targeting Agent

Overview

Journal J Cancer

Specialty Oncology

Date 2016 Feb 27

PMID 26918060

Citations 5

Authors

Ali Baradaran

Khatijah Yusoff

Norazizah Shafee

Raha Abdul Rahim

Affiliations

Soon will be listed here.

Abstract

The hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus (NDV) with its immunotherapeutic activities and sialic acid binding abilities is a promising cancer adjuvant. The HN was surfaced displayed on Lactococcus lactis and its cancer targeting ability was investigated via attachment to the MDA-MB231 breast cancers. To surface display the HN protein on the bacterial cell wall, HN was fused to N-acetylmuraminidase (AcmA) anchoring motif of L. lactis and expressed in Chinese hamster ovary cells. The expressed recombinant fusion proteins were purified and mixed with a culture of L. lactis and Lactobacillus plantarum. Immunofluorescence assay showed the binding of the recombinant HN-AcmA protein on the surface of the bacterial cells. The bacterial cells carrying the HN-AcmA protein interacted with the MDA-MB231 breast cancer cells. Direct and fluorescent microscopy confirmed that L. lactis and Lb. plantarum surface displaying the recombinant HN were attached to the breast cancer MDA-MB231 cells, providing evidence for the potential ability of HN in targeting to cancer cells.

Citing Articles

The multifaceted interactions between Newcastle disease virus proteins and host proteins: a systematic review.

Lu X, Wang X, Liu X, Liu X Virulence. 2024; 15(1):2299182.

PMID: 38193514 PMC: 10793697. DOI: 10.1080/21505594.2023.2299182.

Review detection of Newcastle disease virus.

Mao Q, Ma S, Schrickel P, Zhao P, Wang J, Zhang Y Front Vet Sci. 2022; 9:936251.

PMID: 35982920 PMC: 9378970. DOI: 10.3389/fvets.2022.936251.

Differential Responsiveness to and by Avian Small Intestine Macrophages and T Cells.

Boodhoo N, Shojadoost B, Alizadeh M, Kulkarni R, Sharif S Front Immunol. 2022; 13:807343.

PMID: 35222386 PMC: 8863843. DOI: 10.3389/fimmu.2022.807343.

Secretion of tumoricidal human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by recombinant Lactococcus lactis: optimization of in vitro synthesis conditions.

Ciacma K, Wieckiewicz J, Kedracka-Krok S, Kurtyka M, Stec M, Siedlar M Microb Cell Fact. 2018; 17(1):177.

PMID: 30446013 PMC: 6238363. DOI: 10.1186/s12934-018-1028-2.

A review on Lactococcus lactis: from food to factory.

Song A, In L, Lim S, Rahim R Microb Cell Fact. 2017; 16(1):55.

PMID: 28376880 PMC: 5379754. DOI: 10.1186/s12934-017-0669-x.

References

Mohanty C, Das M, Kanwar J, Sahoo S . Receptor mediated tumor targeting: an emerging approach for cancer therapy. Curr Drug Deliv. 2010; 8(1):45-58. DOI: 10.2174/156720111793663606. View

Ghrici M, El Zowalaty M, Omar A, Ideris A . Induction of apoptosis in MCF-7 cells by the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240. Oncol Rep. 2013; 30(3):1035-44. PMC: 3783058. DOI: 10.3892/or.2013.2573. View

Takimoto T, Taylor G, Connaris H, Crennell S, Portner A . Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion. J Virol. 2002; 76(24):13028-33. PMC: 136693. DOI: 10.1128/jvi.76.24.13028-13033.2002. View

Huang Z, Panda A, Elankumaran S, Govindarajan D, Rockemann D, Samal S . The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence. J Virol. 2004; 78(8):4176-84. PMC: 374304. DOI: 10.1128/jvi.78.8.4176-4184.2004. View

Zeng J, Fournier P, Schirrmacher V . Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology. 2002; 297(1):19-30. DOI: 10.1006/viro.2002.1413. View

Fournier P, Schirrmacher V . Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host. Biology (Basel). 2014; 2(3):936-75. PMC: 3960873. DOI: 10.3390/biology2030936. View

Sihlbom C, van Dijk Hard I, Lidell M, Noll T, Hansson G, Backstrom M . Localization of O-glycans in MUC1 glycoproteins using electron-capture dissociation fragmentation mass spectrometry. Glycobiology. 2008; 19(4):375-81. DOI: 10.1093/glycob/cwn144. View

Varki A, Gagneux P . Multifarious roles of sialic acids in immunity. Ann N Y Acad Sci. 2012; 1253:16-36. PMC: 3357316. DOI: 10.1111/j.1749-6632.2012.06517.x. View

Ni J, Galani I, Cerwenka A, Schirrmacher V, Fournier P . Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity. Vaccine. 2010; 29(6):1185-93. DOI: 10.1016/j.vaccine.2010.12.005. View

10.

Singh R, Bandyopadhyay D . MUC1: a target molecule for cancer therapy. Cancer Biol Ther. 2007; 6(4):481-6. DOI: 10.4161/cbt.6.4.4201. View

11.

Ni J, Schirrmacher V, Fournier P . The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination. Vaccine. 2010; 28(42):6891-900. DOI: 10.1016/j.vaccine.2010.08.011. View

12.

Bull C, Boltje T, Wassink M, de Graaf A, van Delft F, den Brok M . Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Mol Cancer Ther. 2013; 12(10):1935-46. DOI: 10.1158/1535-7163.MCT-13-0279. View

13.

Meany D, Chan D . Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics. 2011; 8(1):7. PMC: 3170274. DOI: 10.1186/1559-0275-8-7. View

14.

Zaitsev V, von Itzstein M, Groves D, Kiefel M, Takimoto T, Portner A . Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion. J Virol. 2004; 78(7):3733-41. PMC: 371092. DOI: 10.1128/jvi.78.7.3733-3741.2004. View

15.

Baradaran A, Sieo C, Foo H, Md Illias R, Yusoff K, Rahim R . Cloning and in silico characterization of two signal peptides from Pediococcus pentosaceus and their function for the secretion of heterologous protein in Lactococcus lactis. Biotechnol Lett. 2012; 35(2):233-8. DOI: 10.1007/s10529-012-1059-4. View

16.

Taylor-Papadimitriou J, Burchell J, Miles D, Dalziel M . MUC1 and cancer. Biochim Biophys Acta. 1999; 1455(2-3):301-13. DOI: 10.1016/s0925-4439(99)00055-1. View

17.

Raha A, Varma N, Yusoff K, Ross E, Foo H . Cell surface display system for Lactococcus lactis: a novel development for oral vaccine. Appl Microbiol Biotechnol. 2005; 68(1):75-81. DOI: 10.1007/s00253-004-1851-8. View

18.

Freire-de-Lima L . Sweet and sour: the impact of differential glycosylation in cancer cells undergoing epithelial-mesenchymal transition. Front Oncol. 2014; 4:59. PMC: 3971198. DOI: 10.3389/fonc.2014.00059. View

19.

Richter E, Wick G . Fluoro-immuno-cytoadherence (FICA): A new method for the identification and enumeration of antigen-binding cells. Z Immunitatsforsch Immunobiol. 1977; 152(5):351-62. View

20.

Reis C, Osorio H, Silva L, Gomes C, David L . Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol. 2010; 63(4):322-9. DOI: 10.1136/jcp.2009.071035. View